Each step carries the legislative work, the regulator-capacity work and the physical-infrastructure work that would need to move together. Years are indicative. Three decision gates mark the moments where those strands need to align — not in lock-step, but close enough that one enables the next.
- Regulatory-framework brief circulated (this document + supporting material)
- Informal conversations with Government of Jersey and States members
- Early conversations with the GMC and the UK Ministry of Justice’s Crown Dependencies team
- Alignment with Digital Jersey, Jersey Business and Jersey Finance on the economic-diversification case
- Consultation with the JCC on framework scope and capacity implications
- Overdale IT specification shaped to support framework data needs
- States motion tabled proposing establishment of a Health Innovation Framework Office
- Public consultation launched on framework scope (which domains, what governance)
- Evidence thresholds for moving from research to authorised treatment published for consultation
- Legislative drafting begins, with trial pathways and research licensing as the first-tranche priority
- Framework-office funding case made to Treasury (private-capital co-investment model)
- Specialist-personnel recruitment programme begins
- First-tranche legislation debated and (target) passed: the Framework Office, trial and research-ethics pathways, and research licensing for controlled substances
- Health Innovation Framework Office established, first head appointed
- Clinical-outcome registry built and tested before the first research participant
- Interoperability policy and common patient ID in place
- Overdale hospital construction on final approach for opening
- New Overdale hospital opens; old General Hospital vacated (target: ~2029–2030)
- First research programmes open inside ethics-approved protocols: psilocybin, MDMA, longevity therapeutics and PGT-P
- Services with established evidence begin under the framework: ketamine quality standards, advanced diagnostics, aesthetics accreditation, the cannabis supply chain
- Second-tranche legislation (advanced therapeutics, diagnostics standards, aesthetics)
- First evidence reviews: results decide which research programmes can become authorised Jersey treatments, which continue, and which stop
- Framework office publishes outcome data from services and research
- Third-tranche legislation if needed (regulatory-body expansion, dispute mechanisms)
- Framework office established as a permanent regulatory arm within Government of Jersey
- First treatments authorised through the research route — the mid-2030s at the earliest
- Framework mature and operating as one of Jersey's regulatory-industry pillars alongside finance, digital and legal
- Continued refinement based on outcome data
Where the strands need to meet.
Three moments where legislation, regulator capacity, evidence and physical infrastructure need to align.
G1 · 2027–2028
Framework office proposed and consultation open, including the evidence thresholds for turning research into treatment. Early work continues under existing law.
G2 · 2029–2030
Research pathway in force and outcome registry live as Overdale opens. Research programmes can open; services with established evidence start under the new rules.
G3 · 2032–2033
Evidence gate. Research results decide which programmes become authorised Jersey treatments and which stop.